Evidence map›Paper›PMID 31689315›Full record

ArticlePloS one2019

Efficacy of interleukin 10 gene hydrofection in pig liver vascular isolated 'in vivo' by surgical procedure with interest in liver transplantation.

Luis Sendra, María José Herrero, Eva María Montalvá, Inmaculada Noguera, Francisco Orbis, Ana Díaz, Rafael Fernández-Delgado, Rafael López-Andújar, Salvador F Aliño

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Luis SendraPharmacogenetics Unit, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
María José HerreroPharmacogenetics Unit, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.ORCID 0000-0002-6042-4185
Eva María MontalváUnit of Experimental Hepatology and Liver Transplantation, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Inmaculada NogueraSCSIE, Central Services of Experimental Support, Universitat de Valencia, Valencia, Spain.
Francisco OrbisHPB Surgery and Transplant Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Ana DíazSCSIE, Central Services of Experimental Support, Universitat de Valencia, Valencia, Spain.
Rafael Fernández-DelgadoPediatrics Unit, Department of Pediatrics, Obstetrics and Gynecology, Universitat de Valencia, Valencia, Spain.
Rafael López-AndújarUnit of Experimental Hepatology and Liver Transplantation, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Salvador F AliñoPharmacogenetics Unit, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
Universitat de València · ESHospital Universitari i Politècnic La Fe · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimLiver transplantation is the only curative strategy for final stage liver diseases. Despite the great advances achieved during the last 20 years, the recipient immune response after transplantation is not entirely controlled. This results in high rates of acute cell rejection and, approximately, 10% of early mortality. Therapeutic treatment could be improved by efficiently transfecting genes that encode natural immunosuppressant proteins, employing safe procedures that could be transferred to clinical setting. In this sense, interleukin 10 plays a central role in immune tolerance response by acting at different levels.

methodshIL10 gene was hydrofected by retrograde hydrodynamic injection in pig liver with complete vascular exclusion mediated by an 'in vivo' surgical procedure. Levels of IL10 DNA, RNA and protein were determined within liver tissue 1 and 10 days after the injection and, more frequently, also the interleukin-10 protein in peripheral blood.

resultsThe procedure was safe for the animals and neither hemodynamic parameters nor liver function determinations showed relevant alterations. The hIL10 hydrofection in watertight liver mediated efficient gene transfer and this was transcribed and translated to protein, achieving up to 110 pg/ml of IL10 in peripheral blood. This value is close to that considered able to reduce the activity of TNFα by half (IL10 IC50 for TNFα = 124 pg/ml).

conclusionsResults of this work suggest that IL10 liver hydrofection with vascular exclusion in vivo is a safe and transferable procedure that mediates plasma protein levels with potential clinical interest in immune modulation after transplantation.

Indexed as

Gene Transfer TechniquesAnimalsEnd Stage Liver DiseaseFemaleGenetic TherapyGenetic VectorsGraft RejectionHumansHydrodynamicsImmune ToleranceInjectionsInterleukin-10LiverLiver TransplantationModels, AnimalPlasmidsIL10 protein, humanInterleukin-10Recombinant Proteins

Identifiers

PMID31689315
PMCPMC6830756
OpenAlexW2988214416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.